Nethia Mohana-Kumaran

Nethia Mohana-Kumaran

Auto-generated profile, based on publicly available information

Nethia Mohana-Kumaran

Universiti Sains Malaysia

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2007 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
AAAndriani Athanasiou
Andriani Athanasiou
ACAnna B. Clarke
Anna B. Clarke
ATAmy E. Turner
Amy E. Turner
NKNethia M. Kumaran
Nethia M. Kumaran
SVSara Vakilpour
Sara Vakilpour
TBTimothy E. Bates
Timothy E. Bates

23 December 2013 in Healthcare
Verified
Journal Article
Open access
PDF file
KBKimberley A. Beaumont
Kimberley A. Beaumont
NMNethia Mohana-Kumaran
Nethia Mohana-Kumaran
NHNikolas Haass
Nikolas Haass
The behavior of melanoma cells has traditionally been studied in vitro in two-dimensional cell culture with cells adhering to plastic dishes. However, in order to mimic the three-dimensional architecture of a melanoma, as well as its interactions with the tumor microenvironment, there has been the need for more physiologically relevant models. This has been achieved by designing 3D in vitro models of melanoma, such as melanoma spheroids embedded in extracellular matrix or organotypic skin reconstructs. In vivo melanoma models have typically relied on the growth of tumor xenografts in immunocompromised mice. Several genetically engineered mouse models have now been developed which allow the generation of spontaneous melanoma. Melanoma models have also been established in other species such as zebrafish, which are more conducive to imaging and high throughput studies. We will discuss these models as well as novel techniques that are relevant to the study of the molecular mechanisms underlying melanoma progression.

31 January 2012 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
KLKeryn M. Lucas
Keryn M. Lucas
NMNethia Mohana-Kumaran
Nethia Mohana-Kumaran
DLDiana Lau
Diana Lau
XZXu Dong Zhang
Xu Dong Zhang
PHPeter Hersey
Peter Hersey
JAJohn D. Allen
John D. Allen
Purpose: Drug resistance in melanoma is commonly attributed to ineffective apoptotic pathways. Inhibiting antiapoptotic BCL-2 and its relatives is an attractive strategy for sensitizing lymphoid malignancies to drugs but it has been largely unsuccessful for melanoma and other solid tumors. ABT-737, a small-molecule BH3-mimetic, selectively inhibits BCL-2, BCL-XL, and BCL-w and shows promise for treating leukemia, lymphoma, and small-cell lung cancer. Melanoma cells are insensitive to ABT-737, but MCL-1 inhibition reportedly increases the sensitivity of other tumors to the compound. Experimental Design: The efficacy of MCL-1 and BFL-1 inhibition for sensitizing melanoma cells to ABT-737 was investigated by short hairpin RNA–mediated knockdown or overexpression of their antagonist NOXA in two-dimensional cell culture, a three-dimensional organotypic spheroid model, and an in vivo model. Results: MCL-1 downregulation or NOXA overexpression strongly sensitized melanoma cells to ABT-737 in vitro. NOXA-inducing cytotoxic drugs also strongly sensitized melanomas to ABT-737 but, surprisingly, not vice versa. The drugs most suitable are not necessarily those normally used to treat melanoma. Resistance to ABT-737 occurred quickly in three-dimensional melanoma spheroids through reduced NOXA expression, although experiments with both xenografts and three-dimensional spheroids suggest that penetration of ABT-737 into tumor masses may be the principal limitation, which may be obviated through use of more diffusible BH3-mimetics. Conclusion: Sensitization of tumors to BH3-mimetics by cytotoxic drugs that induce NOXA is a therapeutic strategy worth exploring for the treatment of melanoma and other solid cancers. Clin Cancer Res; 18(3); 783–95. ©2011 AACR.

1 March 2007 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
AAAndriani Athanasiou
Andriani Athanasiou
PSPaul A. Smith
Paul A. Smith
SVSara Vakilpour
Sara Vakilpour
NKNethia M. Kumaran
Nethia M. Kumaran
ATAmy E. Turner
Amy E. Turner
TBTimothy E. Bates
Timothy E. Bates

21 March 2014 in Pigment Cell & Melanoma Research
Verified
Journal Article
Open access
PDF file
NMNethia Mohana‐Kumaran
Nethia Mohana‐Kumaran
DHDavid S. Hill
David S. Hill
JAJohn D. Allen
John D. Allen
NHNikolas Haass
Nikolas Haass
Summary: Melanoma drug resistance is often attributed to abrogation of the intrinsic apoptosis pathway. Targeting regulators of apoptosis is thus considered a promising approach to sensitizing melanomas to treatment. The development of small‐molecule inhibitors that mimic natural antagonists of either antiapoptotic members of the BCL‐2 family or the inhibitor of apoptosis proteins (IAPs), known as BH3‐ or SMAC‐mimetics, respectively, are helping us to understand the mechanisms behind apoptotic resistance. Studies using BH3‐mimetics indicate that the antiapoptotic BCL‐2 protein MCL‐1 and its antagonist NOXA are particularly important regulators of BCL‐2 family signaling, while SMAC‐mimetic studies show that both XIAP and the cIAPs must be targeted to effectively induce apoptosis of cancer cells. Although most solid tumors, including melanoma, are insensitive to these mimetic drugs as single agents, combinations with other therapeutics have yielded promising results, and tests combining them with BRAF‐inhibitors, which have already revolutionized melanoma treatment, are a clear priority.

20 October 2012 in Carcinogenesis
Verified
Journal Article
Closed access
PDF file
DWDavid Wroblewski
David Wroblewski
BMBranka Mijatov
Branka Mijatov
NMNethia Mohana-Kumaran
Nethia Mohana-Kumaran
FLFritz Lai
Fritz Lai
SGStuart Gallagher
Stuart Gallagher
Peter HerseyPeter Hersey
Peter Hersey
Although the introduction of selective v-Raf murine sarcoma viral oncogene homolog B1 (BRAF) inhibitors has been a major advance in treatment of metastatic melanoma, approximately 50% of patients have limited responses including stabilization of disease or no response at all. This study aims to identify a novel means of overcoming resistance of melanoma to killing by BRAF inhibitors. We examined the influence of the BH3-mimetic ABT-737 on induction of apoptosis by the selective BRAF inhibitor PLX4720 in melanoma cells with or without BRAF V600E mutation. Included were cell lines established from four patients before and during treatment with selective BRAF inhibitors and 3D spheroids derived from these cell lines. Cell lines with no or low sensitivity to PLX4720 underwent synergistic increases and increased rates of apoptosis when combined with ABT-737. This degree of synergism was not seen in cell lines without BRAF V600E mutations. Apoptosis was mediated through the mitochondrial pathway and was due in part to upregulation of Bim as shown by inhibition of apoptosis following small interfering RNA knockdown of Bim. Similar effects were seen in cell lines established from patients prior to treatment but not in lines from patients clinically resistant to the selective BRAF inhibitors and in 3D spheroids derived from these cell lines. These results suggest that combination of selective BRAF inhibitors with ABT-737 or the related orally available compound ABT-263 may increase the degree and rate of responses in previously untreated patients with V600E melanoma but not in those with acquired resistance to these agents.